{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=emtricitabine%2Ftenofovir+disoproxil+fumarate+%28FTC%2FTDF%29&page=8", "query": { "intervention": "emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 234, "total_pages": 24, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=emtricitabine%2Ftenofovir+disoproxil+fumarate+%28FTC%2FTDF%29&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=emtricitabine%2Ftenofovir+disoproxil+fumarate+%28FTC%2FTDF%29&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T00:08:56.222Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00959894", "title": "Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Etravirine (Intelence)", "type": "DRUG" }, { "name": "Truvada", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2009-09", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2016-06-06", "last_synced_at": "2026-10-14T00:08:56.222Z", "location_count": 3, "location_summary": "Chapel Hill, North Carolina • Charlotte, North Carolina • Winston-Salem, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00959894" }, { "nct_id": "NCT05108935", "title": "Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Opioid Use", "Opioid Use Disorder", "Risk Reduction", "Hiv", "Hepatitis C" ], "interventions": [ { "name": "Suboxone", "type": "DRUG" }, { "name": "Truvada", "type": "DRUG" }, { "name": "Mavyret", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2022-02-17", "completion_date": "2023-03-30", "has_results": false, "last_update_posted_date": "2023-04-27", "last_synced_at": "2026-10-14T00:08:56.222Z", "location_count": 2, "location_summary": "Durham, North Carolina • Greensboro, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Greensboro", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05108935" }, { "nct_id": "NCT01854775", "title": "Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Acquired Immune Deficiency Syndrome (AIDS)", "HIV Infections" ], "interventions": [ { "name": "E/C/F/TAF", "type": "DRUG" }, { "name": "E/C/F/TAF (Low Dose)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 129, "start_date": "2013-05-06", "completion_date": "2025-06-18", "has_results": true, "last_update_posted_date": "2026-01-09", "last_synced_at": "2026-10-14T00:08:56.222Z", "location_count": 5, "location_summary": "Long Beach, California • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01854775" }, { "nct_id": "NCT02707601", "title": "Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection", "HCV Infection" ], "interventions": [ { "name": "E/C/F/TAF", "type": "DRUG" }, { "name": "F/R/TAF", "type": "DRUG" }, { "name": "LDV/SOF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2016-04-01", "completion_date": "2017-09-29", "has_results": true, "last_update_posted_date": "2018-11-14", "last_synced_at": "2026-10-14T00:08:56.222Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02707601" }, { "nct_id": "NCT00262522", "title": "Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Human Immunodeficiency Virus Infections" ], "interventions": [ { "name": "lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 664, "start_date": "2005-11", "completion_date": "2008-07", "has_results": true, "last_update_posted_date": "2012-02-06", "last_synced_at": "2026-10-14T00:08:56.222Z", "location_count": 30, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Fountain Valley, California + 23 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00262522" }, { "nct_id": "NCT00244712", "title": "Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "emtricitabine/tenofovir", "type": "DRUG" }, { "name": "abacavir/lamivudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 688, "start_date": "2005-07", "completion_date": "2008-04", "has_results": true, "last_update_posted_date": "2010-06-08", "last_synced_at": "2026-10-14T00:08:56.222Z", "location_count": 72, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00244712" }, { "nct_id": "NCT05378399", "title": "SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections", "Substance Use", "Adherence, Medication", "Adherence, Treatment" ], "interventions": [ { "name": "Descovy or Truvada", "type": "DRUG" }, { "name": "ID-Cap System", "type": "DEVICE" }, { "name": "Beiwe", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 40, "start_date": "2022-12-20", "completion_date": "2026-03-31", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-10-14T00:08:56.222Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05378399" }, { "nct_id": "NCT03472963", "title": "Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Single dose of Genvoya® and a single 800 mg dose of Darunavir®", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "MALE", "summary": "18 Years to 49 Years · Male only" }, "enrollment_count": 35, "start_date": "2018-04-27", "completion_date": "2019-03-29", "has_results": false, "last_update_posted_date": "2020-08-28", "last_synced_at": "2026-10-14T00:08:56.222Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03472963" }, { "nct_id": "NCT02431247", "title": "A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Immunodeficiency Virus Type 1, Human" ], "interventions": [ { "name": "Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC", "type": "DRUG" }, { "name": "DRV/COBI FDC", "type": "DRUG" }, { "name": "FTC/TDF FDC", "type": "DRUG" }, { "name": "D/C/F/TAF FDC - Matching Placebo", "type": "DRUG" }, { "name": "FTC/TDF FDC Matching Placebo", "type": "DRUG" }, { "name": "DRV/COBI FDC Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Sciences Ireland UC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 725, "start_date": "2015-07-06", "completion_date": "2020-09-30", "has_results": true, "last_update_posted_date": "2022-09-28", "last_synced_at": "2026-10-14T00:08:56.222Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02431247" }, { "nct_id": "NCT00924898", "title": "Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Acute HIV Infection", "HIV Infections" ], "interventions": [ { "name": "efavirenz, emtricitabine, and tenofovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2005-01", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2017-05-16", "last_synced_at": "2026-10-14T00:08:56.222Z", "location_count": 2, "location_summary": "Chapel Hill, North Carolina • Durham, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00924898" } ] }